Keywords: novartis, invest, skyepharma, return, dry, powder, inhaler
Novartis Invest in SkyePharma In Return for Dry Powder Inhaler
Article | 19 November 1998
Novartis has taken a 2% stake in SkyePharma under which it willmake a L6 million ($10.1 million) equity investment in return for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
